Kiat Ruxrungtham

Summary

Affiliation: Chulalongkorn University
Country: Thailand

Publications

  1. pmc A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais
    Supranee Buranapraditkun
    Vaccine and Cellular Immunology Laboratory, Chulalongkorn Medical Research Center ChulaMRC, and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    PLoS ONE 6:e23603. 2011
  2. doi request reprint Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227
    K Ruxrungtham
    HIV NAT, Thai Red Cross AIDS Research Center and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    HIV Med 9:883-96. 2008
  3. pmc Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
    Anchalee Avihingsanon
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS Res Ther 9:6. 2012
  4. ncbi request reprint Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 13:375-80. 2008
  5. ncbi request reprint Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 11:631-5. 2006
  6. doi request reprint Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Antimicrob Chemother 61:1340-3. 2008
  7. ncbi request reprint Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Pathumwan, Bangkok, Thailand
    AIDS Res Hum Retroviruses 28:1170-6. 2012
  8. doi request reprint Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors
    Torsak Bunupuradah
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Int J Infect Dis 14:e311-6. 2010
  9. ncbi request reprint Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients
    Mark Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 10:301-7. 2005
  10. doi request reprint Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy
    Torsak Bunupuradah
    HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Neurovirol 18:479-87. 2012

Collaborators

Detail Information

Publications76

  1. pmc A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais
    Supranee Buranapraditkun
    Vaccine and Cellular Immunology Laboratory, Chulalongkorn Medical Research Center ChulaMRC, and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    PLoS ONE 6:e23603. 2011
    ..Unfortunately, little is known about the CD8+ T cell responses against CRF01_AE, which is responsible for the majority of infections in Southeast Asia...
  2. doi request reprint Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227
    K Ruxrungtham
    HIV NAT, Thai Red Cross AIDS Research Center and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    HIV Med 9:883-96. 2008
    ....
  3. pmc Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
    Anchalee Avihingsanon
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS Res Ther 9:6. 2012
    ..abstract:..
  4. ncbi request reprint Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 13:375-80. 2008
    ..The aim of this study was to assess the long-term efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs)...
  5. ncbi request reprint Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 11:631-5. 2006
    ..There are few data on the selection of resistance by ritonavir-boosted saquinavir (SQV/r), particularly in antiretroviral (ARV)-naive patients...
  6. doi request reprint Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Antimicrob Chemother 61:1340-3. 2008
    ..Here, we evaluated the effect of switching from stavudine/didanosine to tenofovir/lamivudine on measures of metabolic and mitochondrial toxicity in Thai patients...
  7. ncbi request reprint Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Pathumwan, Bangkok, Thailand
    AIDS Res Hum Retroviruses 28:1170-6. 2012
    ..Despite good virological outcome in our cohort, prolonged exposure to subtherapeutic indinavir concentrations may lead to treatment failure...
  8. doi request reprint Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors
    Torsak Bunupuradah
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Int J Infect Dis 14:e311-6. 2010
    ..To evaluate outcomes in dual nucleoside reverse transcriptase inhibitor (NRTI) pretreated children after genotyping (GT)...
  9. ncbi request reprint Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients
    Mark Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 10:301-7. 2005
    ..To study the pharmacokinetics of indinavir/ ritonavir 400/100 mg twice daily in antiretroviral-naive patients at Srinagarind Hospital in Khon Kaen, Thailand...
  10. doi request reprint Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy
    Torsak Bunupuradah
    HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Neurovirol 18:479-87. 2012
    ..three out of four in TDF/3TC/LPV/r arm. The rates of NCI and depression did not differ among cases failing NNRTI-based cART who received mLPV/r compared to LPV/r triple therapy...
  11. ncbi request reprint Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children
    Thanyawee Puthanakit
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    J Antimicrob Chemother 64:1080-6. 2009
    ..Several studies have shown higher plasma concentrations of antiretroviral agents in Thai adults than in Caucasians, suggesting that lower doses may be used...
  12. ncbi request reprint A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 10:761-7. 2005
    ....
  13. doi request reprint Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, Bangkok, Thailand
    Antivir Ther 14:1001-4. 2009
    ..However quality and safety remains an issue of concern. Therefore, we evaluated minimal plasma concentrations and short-term safety of a generic lopinavir/ritonavir 200/50 mg tablet formulation...
  14. ncbi request reprint Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients
    Reshma Saskia Autar
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    AIDS 21:1535-9. 2007
    ..However, toxicity, storage conditions and high costs of antiretroviral treatment may necessitate interruption of ritonavir. Ketoconazole was investigated as a potential booster of once-daily (o.d.) saquinavir...
  15. ncbi request reprint Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment
    Reto Nuesch
    HIV Netherlands, Australia, Thailand Research Collaboration HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Clin Infect Dis 40:728-34. 2005
    ..One major concern, however, is the development of resistance to antiretroviral drugs that can occur during multiple cycles of starting and stopping therapy...
  16. ncbi request reprint Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors
    Sunee Sirivichayakul
    Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    AIDS 17:1889-96. 2003
    ..To investigate genotypic drug resistance in HIV-1 subtype A/E infection associated with failure of double/triple-nucleoside reverse transcriptase (RT) inhibitor therapy...
  17. ncbi request reprint Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012)
    Mark A Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Infect Dis 194:1319-22. 2006
    ..62+/-0.34 per day and -0.51+/-0.16 per day; P>.1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor...
  18. ncbi request reprint Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection
    Reto Nuesch
    HIV NAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    AIDS 22:152-4. 2008
    ..Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted...
  19. doi request reprint Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens
    Torsak Bunupuradah
    HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 16:1113-21. 2011
    ..We studied prevalence of etravirine (ETR) and rilpivirine (RPV) resistance in HIV-1 subtype CRF01_AE infection with first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) failure...
  20. ncbi request reprint Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Antivir Ther 11:223-32. 2006
    ..The use of HIV protease inhibitors (PIs) in a ritonavir (RTV)-boosted form is now common. However, randomized data comparing boosted with unboosted PI strategies are scarce...
  21. ncbi request reprint A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection
    Peter G Cardiello
    The HIV Netherlands Australia Thailand Research Collaborative, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Clin Infect Dis 40:594-600. 2005
    ....
  22. ncbi request reprint Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    J Acquir Immune Defic Syndr 39:523-9. 2005
    ..To assess the safety of 2 intermittent treatment strategies compared with continuous therapy for patients with virologic suppression on highly active antiretroviral therapy (HAART) at baseline...
  23. pmc Impact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT study
    Torsak Bunupuradah
    1 HIV Netherlands Australia Thailand HIV NAT Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand
    AIDS Patient Care STDS 27:596-603. 2013
    ..In conclusion, no significant difference of QOL scores between treatment groups. Early ART commencement associated with greater increase of QOL scores over 144 weeks. QOL scores in HIV-infected children were lower than healthy controls...
  24. pmc Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use
    Thanyawee Puthanakit
    HIV Netherlands Australia Thailand HIV NAT Research Collaboration, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Pediatr Infect Dis J 32:252-3. 2013
    ..9-8.5%) among Cambodian children. HLA-B*5701 carriage is not uncommon among Thai and Cambodian children; it is close to the prevalence found in European and higher than the prevalence found in East Asian and African studies...
  25. doi request reprint A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study
    Torsak Bunupuradah
    HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 17:1351-61. 2012
    ..There are also no randomized trials addressing treatment options after failing first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-regimens...
  26. ncbi request reprint Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection
    Chaiwat Ungsedhapand
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 36:693-701. 2004
    ..Triple-nucleoside therapy with ZDV, 3TC, and ddI or d4T, 3TC, and ABC in patients with HIV infection is more effective in inducing a sustained virologic response than the dual combinations of ZDV and 3TC or ddI and d4T...
  27. ncbi request reprint Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration and the Thai Red Cross AIDS Research Center, Bangkok, Thailand
    AIDS 19:185-92. 2005
    ..To determine the incidence and risk factors for rash in Thai patients taking four different non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens...
  28. ncbi request reprint Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz
    Mark A Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Infect Dis 194:642-50. 2006
    ..Improvements in lipoatrophy after a switch in nucleoside reverse-transcriptase inhibitors (NRTIs) have been demonstrated. We investigated 60 patients switching from failed NRTIs to ritonavir-boosted indinavir and efavirenz...
  29. pmc Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antimicrob Agents Chemother 56:1892-8. 2012
    ..However, raltegravir at 400 mg QD was associated with a low C(trough) and with a risk for HIV viremia. Raltegravir at 200 or 300 mg BID should be studied, but new raltegravir formulations will be needed...
  30. ncbi request reprint Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients
    Reshma Saskia Autar
    The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    J Antimicrob Chemother 56:908-13. 2005
    ..Differential exposure to saquinavir/ritonavir may lead to therapy failure. The objective was to identify factors that influence variability of saquinavir/ritonavir plasma concentrations...
  31. ncbi request reprint Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis
    Reshma S Autar
    The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Antivir Ther 10:937-43. 2005
    ..However, limited data are available about whether or not nevirapine and rifampin can be safely coadministered without the plasma concentration of nevirapine falling below therapeutic levels...
  32. pmc Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study
    Thanyawee Puthanakit
    HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Pediatr Infect Dis J 32:501-8. 2013
    ..We now report neurodevelopmental outcomes...
  33. pmc Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial
    Thanyawee Puthanakit
    HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Lancet Infect Dis 12:933-41. 2012
    ..We assessed whether antiretroviral therapy could be deferred until CD4 percentages declined to less than 15% without affecting AIDS-free survival...
  34. doi request reprint Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand
    Anchalee Avihingsanon
    HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 15:917-22. 2010
    ..However, there is limited randomized data on the efficacy of combined therapy with TDF and FTC, especially in antiretroviral (ARV)-naive patients...
  35. doi request reprint Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 25:1299-303. 2011
    ..To investigate whether Thai HIV-1-infected pregnant women require a dose increase of lopinavir/ritonavir (LPV/r) and to assess the safety and efficacy of the generic tablets during pregnancy...
  36. ncbi request reprint HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting
    Chris Duncombe
    HIV Netherlands Australia Thailand Research Collaboration, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    AIDS 19:169-78. 2005
    ..DESIGN, SETTING, PARTICIPANTS AND INTERVENTION: A cohort of 417 patients enrolled in a series of randomized ART trials, between 1996 and December 2002...
  37. ncbi request reprint Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens
    Stephen J Kerr
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Int Assoc Physicians AIDS Care (Chic) 6:36-46. 2007
    ..Non-stavudine-containing non-boosted protease-inhibitor-based highly active antiretroviral treatment regimens had the least association with dyslipidemia...
  38. pmc Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients
    Anchalee Avihingsanon
    1 HIV Netherlands Australia Thailand HIV NAT Research Collaboration, Thai Red Cross AIDS Research Center Bangkok, Bangkok, Thailand
    AIDS Res Hum Retroviruses 29:1541-6. 2013
    ..Patients from the aging group appeared to have higher atazanavir exposure compared to the younger group. Further PK explorations of ATV in the extremely aged population are warranted...
  39. ncbi request reprint Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects
    Peter G Cardiello
    HIV Netherlands Australia Thailand Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 32:375-9. 2003
    ..To investigate the pharmacokinetics of once-daily saquinavir (SQV) hard-gelatin capsule (HGC)/ritonavir (RTV), 1600/100 mg, compared with once-daily SQV soft-gelatin capsule (SGC)/RTV, 1600/100 mg...
  40. ncbi request reprint CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Lancet 368:459-65. 2006
    ..Stopping antiretroviral therapy in patients with HIV-1 infection can reduce costs and side-effects, but carries the risk of increased immune suppression and emergence of resistance...
  41. doi request reprint Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries
    Meena Gorowara
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Curr Opin HIV AIDS 5:90-6. 2010
    ..Potential risk for the increase in toxicity due to higher drug exposure among Asians is also a concern. In this article, we discuss the studies performed using low-dose antiretroviral therapy as an effective and well tolerated strategy...
  42. ncbi request reprint HIV drug resistance transmission threshold survey in Bangkok, Thailand
    Sunee Sirivichayakul
    Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Antivir Ther 13:109-13. 2008
    ..Because viral load and resistance testing are not widely available, unidentified HIV drug resistance (HIVDR) may occur during treatment and could be transmitted...
  43. doi request reprint Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 23:1176-9. 2009
    ..The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered...
  44. ncbi request reprint Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008
    Somnuek Sungkanuparph
    Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand
    J Med Assoc Thai 91:1925-35. 2008
    ....
  45. pmc Prevalence of anemia and underlying iron status in naive antiretroviral therapy HIV-infected children with moderate immune suppression
    Pope Kosalaraksa
    Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
    AIDS Res Hum Retroviruses 28:1679-86. 2012
    ..A routine prescription of iron supplement in anemic HIV-infected children without laboratory confirmation of IDA should be discouraged, especially in regions with a high prevalence of thalassemia and low prevalence of IDA...
  46. doi request reprint Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents
    Arunee Klinklom
    Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Antivir Ther 17:283-9. 2012
    ..Previous data showed high plasma concentrations of LPV in Thai patients. This study determined the pharmacokinetic (PK) parameters of a low-dose LPV/r tablet (70% of standard dose) in HIV-infected Thai adolescents...
  47. ncbi request reprint Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Pharmacogenet Genomics 16:321-9. 2006
    ..To investigate the association between the UGT1A1*6 (G71R) and UGT1A1*28 (promoter (TA)7-repeat) genotypes and hyperbilirubinaemia in Thai patients treated with indinavir, and characterize the inhibition of human UGTs by indinavir in vitro...
  48. doi request reprint Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Acquir Immune Defic Syndr 59:55-8. 2012
    ..All patients remained virologically suppressed at week 12. In conclusion, LPV/r 200/50mg BID does not lead to adequate lopinavir plasma concentrations. Generic and branded LPV/r have comparable PK-parameters...
  49. ncbi request reprint Significant differences between plasma HIV-1 RNA assays in HIV-1 subtype E infected patients treated with antiretroviral therapy
    Kiat Ruxrungtham
    The Netherlands, Australia Thailand Research Collaboration HIV NAT, Thai Red Cross AIDS Research Centre, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Asian Pac J Allergy Immunol 20:105-11. 2002
    ..As the current goal of therapy is to suppress plasma viral load below the detection limit of the assays, the significant differences between the assays may influence antiretroviral efficacy evaluation and management...
  50. doi request reprint Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting
    Somsamorn Mangclaviraj
    Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Int J STD AIDS 19:529-32. 2008
    ..In settings where access to affordable treatment is improving, this study reinforces the importance of regular Pap smear screening in HIV-positive women, particularly those with low nadir CD4 counts and lower incomes...
  51. ncbi request reprint Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin
    Anchalee Avihingsanon
    HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 13:529-36. 2008
    ..We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin...
  52. ncbi request reprint The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Antivir Ther 14:443-50. 2009
    ..Pregnancy affects the pharmacokinetics of most protease inhibitors. Saquinavir, when administered in a tablet formulation, has not been studied extensively in this setting...
  53. ncbi request reprint Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand
    Reto Nuesch
    HIV Netherlands Australia Thailand Research Collaboration and the Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Antimicrob Chemother 58:637-44. 2006
    ..Time-dependent occurrence of grade III/IV abnormal laboratory values as defined by the AIDS Clinical Trial Group was analysed...
  54. ncbi request reprint Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin
    Weerawat Manosuthi
    Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    AIDS 19:1481-6. 2005
    ..Concomitant use of efavirenz and rifampicin is common for treatment of HIV and tuberculosis. Plasma efavirenz levels can be reduced by rifampicin, but the appropriate daily dosage of efavirenz is unclear...
  55. doi request reprint Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand HIV NAT Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 19:41-9. 2014
    ..Vitamin D insufficiency plays an important role in the development of fibrosis in chronic liver disease...
  56. pmc Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure
    Simone Langford
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Open Virol J 2:69-73. 2008
    ..004). The last HIV RNA below 50 copies/ml was significantly higher among cases compared to controls (p=.004). Measuring HIV RNA below 50 copies/ml may be useful in predicting virological failure to STI...
  57. pmc An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection
    Atchriya Hemachandra
    HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Hum Vaccin 6:835-40. 2010
    ..Previously demonstrated safe and highly immunogenic in non-human primates, this study assessed DNA (pHIS-HIV-AE) prime, recombinant fowlpox (rFPV-HIV-AE) boost vaccines in humans...
  58. ncbi request reprint Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study
    Peter G Cardiello
    HIV Netherlands Australia Thailand Research Collaborative HIVNAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    J Acquir Immune Defic Syndr 29:464-70. 2002
    ....
  59. ncbi request reprint Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks
    Torsak Bunupuradah
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 14:241-8. 2009
    ....
  60. pmc Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12 years of age
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand
    J Allergy Clin Immunol 126:1294-301.e10. 2010
    ..There are limited data on the immune profiles of HIV-positive children compared with healthy controls, and no such data for Asian children...
  61. ncbi request reprint Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection
    Rathapon Asasutjarit
    Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
    Pharm Res 24:1098-107. 2007
    ....
  62. pmc Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients
    Kearkiat Praditpornsilpa
    Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Bangkok, Thailand
    AIDS 26:1781-8. 2012
    ..We validated the available eGFR equations and compared them to the plasma Tc-diethylenetriaminepentaacetic acid (Tc-DTPA) clearance in HIV-infected patients...
  63. doi request reprint Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets
    Thanyawee Puthanakit
    HIVNAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Pediatr Infect Dis J 29:79-82. 2010
    ..7 (5.0-9.9) mg/L. All the children had C trough >1.0 mg/L and 96% had values >4.0 mg/L. LPV/r adult tablets can be used in children when it is necessary...
  64. doi request reprint Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study
    Wadchara Pumpradit
    HIV NAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    J Neurovirol 16:76-82. 2010
    ..Three subjects (4.7%) had depression and no cases had significant symptoms of anxiety. A notable proportion of well-controlled individuals exhibited neurocognitive impairment. Anxiety and depression were uncommon...
  65. pmc Poor quality of life among untreated Thai and Cambodian children without severe HIV symptoms
    Torsak Bunupuradah
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand
    AIDS Care 24:30-8. 2012
    ..QOL assessment should be considered in untreated children to inform decisions about when to initiate ART...
  66. doi request reprint Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand
    Hai Le Nguyen
    Vaccine and Cellular Immunology Laboratory, Vaccine Research Center, Chulalongkorn University, Bangkok, Thailand
    J Med Virol 84:713-20. 2012
    ..Systematic monitoring of primary resistance transmission in Thailand and this region is essential to guide whether genotypic resistance test is required prior to commencing the first-line highly active antiretroviral therapy (HAART)...
  67. ncbi request reprint Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 34:134-9. 2003
    ....
  68. doi request reprint Characterization of hepatitis B virus mutations in untreated patients co-infected with HIV and HBV based on complete genome sequencing
    Pisit Tangkijvanich
    Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    J Med Virol 85:16-25. 2013
    ..There was no major difference in the frequencies of common HBV mutations between co-infected and mono-infected patients. Thus, HBV mutations may not contribute to disease pathogenesis in Thai patients with co-infection...
  69. ncbi request reprint Cost savings by reagent reduction in flow cytometry-based CD4+ T cell counts: an approach to improve accessibility for HIV management
    Supranee Buranapraditkun
    Division of Allergy and Clinical Immunology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand
    Asian Pac J Allergy Immunol 25:83-9. 2007
    ..Such an approach will significantly reduce the cost of CD4+ monitoring for resource limited settings where a flow cytometer is available...
  70. ncbi request reprint HIV/AIDS in Asia
    Kiat Ruxrungtham
    Faculty of Medicine, Chulalongkorn University, the Thai Red Cross AIDS Research Centre and HIV NAT, Bangkok 10330, Thailand
    Lancet 364:69-82. 2004
    ..Genuine political interest and commitment are essential foundations for success, demanding advocacy at all levels to drive policy, mobilise sufficient resources, and take effective action...
  71. doi request reprint Immunogenicity assay validation for an HIV vaccine trial: high IFNγ+/IL-2+ CD8+ T cells background in healthy Thais
    Sunee Sirivichayakul
    Faculty of Medicine, Chulalongkorn University, Rama IV Road, Pathumwan, Bangkok 10330, Thailand
    Vaccine 29:6002-7. 2011
    ..The determinates of these unexpected responses were explored and minimized...
  72. doi request reprint Impact of baseline virologic, immunologic, and demographic characteristics on virologic responses in the Gemini study
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    HIV Clin Trials 13:111-7. 2012
    ..To determine the impact of baseline viral load (VL) and CD4+ cell count, race/ethnicity, and gender on response in a post hoc analysis of the Gemini study...
  73. ncbi request reprint Eosinophil count in nasal mucosa is more suitable than the number of ICAM-1-positive nasal epithelial cells to evaluate the severity of house dust mite-sensitive allergic rhinitis: a clinical correlation study
    Jettanong Klaewsongkram
    Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Int Arch Allergy Immunol 132:68-75. 2003
    ..The purpose of this study was to evaluate correlations between clinical and laboratory parameters in patients with HDM-sensitive allergic rhinitis...
  74. doi request reprint Alkali-treated penicillin G solution is a better option than penicillin G as an alternative source of minor determinants for penicillin skin test
    Pongsak Wangrattanasopon
    Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Allergy Asthma Proc 33:152-9. 2012
    ..Minor determinants play a significant role for penicillin allergy in Thailand and should be included in the penicillin skin test panel to verify suspected cases of penicillin allergy. (ClinicalTrials.gov number: NCT00789217)...
  75. ncbi request reprint Construction and immunogenicity study of a 297-bp humanized HIV V3 DNA of an approximated last common ancestor in mice
    Sunee Sirivichayakul
    Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Asian Pac J Allergy Immunol 22:49-60. 2004
    ..Moreover, intracellular and extracellular interferon-gamma could be detected upon in vitro stimulation of spleen cells although the response was relatively weak. Further improvement of our humanized V3 DNA is needed...